Full Description
The World Stroke Organization reports that "stroke has already reached epidemic proportions. Globally1 in 4 adults over the age of 25 will have a stroke in their lifetime. 12.2 million people worldwide will have their first stroke this year, and 6.5 million will die as a result." Ischemic strokes are the most common type of stroke, with about 87% of all strokes being ischemic strokes.
This new volume addresses this epidemic by presenting detailed studies on ischemic injury, with emphasis on the molecular-level mechanisms and the role of signaling pathways in the body, their structure, and their mechanism of action. The book focuses on molecular pharmacology plans and explains the new areas of research on the discovery of therapeutic molecules that can be used for combating this life-threatening disease. The authors discuss stroke occurrence at different stages of life as well as sex-based differences in its treatment. They cover aspects of the clinical treatment and diagnosis of patients with cardiovascular events, including in-depth information on the prevention, evaluation, therapy selection, result projection, and long-term course of the disease in affected patients. They also detail the involvement of platelets, neurotransmitters, renin-angiotensin-aldosterone system, and vitamin D in ischemic injury.
Contents
1. Stroke Insight 2. Myocardial Ischemic-Reperfusion Injury 3. Preclinical and Clinical Aspects of I-R Injuries 4. Molecular Aspects of Ischemic-Reperfusion Injury 5. Role of Mitochondria in Ischemic-Reperfusion Injury 6. Stroke Effect in Daily Life and Therapeutics, Complications for Prevention of Stroke 7. Etiopathogenesis and Molecular Targets in Cerebral Ischemia: Current Understanding of Stroke and Therapeutic Approaches 8. Expatiating the Pivotal Role of Matrix Metalloproteinases and Blood-Brain Barrier Disruption in Ischemic Stroke: Molecular Insights and Therapeutic Targets 9. Acute Ischemic Stroke in COVID-19 Patients 10. Neurotransmission Imbalance: A Major Factor in the Worsening of Ischemic Injury 11. Role of the Renin-Angiotensin-Aldosterone System (RAAS) in Amelioration of Stroke Pathophysiology 12. Stroke and Diabetes in Vitamin D Deficiency: Prospects of Intertwined Pathobiologies 13. Remote Ischemic Post-Conditioning: An Overview 14. Sex-Based Differences in Acute Kidney Injury: Lessons from Renal Ischemia-Reperfusion Injury Model in Rodents 15. Critical Overview of Conditioning Techniques and Their Current Status in the Treatment of Myocardial Ischemia-Reperfusion Injury 16. Involvement of Platelets in Myocardial Ischemia and Reperfusion Injury 17. Recent Advancements in Strategies for Treatment of Cerebral Ischemia 18. Recent Therapeutic Approaches Toward the Management of Ischemic Heart Disease 19. Nanotechnology-Assisted Treatment for Ischemic Heart Disease and Recent Patents 20. Major Risk Factors Involved in the Pathobiology of Ischemic Brain and Heart Disorders 21. Modulating Mitogen-Activated Protein Kinase (MAPK) Downstream Signaling Pathways in Cerebral Ischemic Hemorrhages 22. Implication of Mitogen-Activated Protein Kinase (MAPK) in Cerebral Stroke 23. Regulation of JNK Signaling Pathway in Ischemia-Reperfusion Injury 24. Role of Glycogen Synthase Kinase-3? (Gsk-3?) in Intracranial Haemorrhage 25. Role of GSK-3 Inhibition in Modulating the Pathology of Stroke 26. Regulation of NRF-2 Signaling Pathway in Ischemia-Reperfusion Injury 27. Regulation of PI3K-AKT Signaling Pathway in Ischemia-Reperfusion Injury 28. COVID-19 and Ischemic Stroke: Advancements and Challenges
